These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32583656)

  • 41. Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men.
    Chattopadhyay A; Bhansali A; Masoodi SR
    Pituitary; 2005; 8(2):147-54. PubMed ID: 16379032
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
    Sabuncu T; Arikan E; Tasan E; Hatemi H
    Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Medically induced CSF rhinorrhea following treatment of macroprolactinoma: case series and literature review.
    Česák T; Poczos P; Adamkov J; Náhlovský J; Kašparová P; Gabalec F; Čelakovský P; Choutka O
    Pituitary; 2018 Dec; 21(6):561-570. PubMed ID: 30116971
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma.
    Raverot G; Jacob M; Jouanneau E; Delemer B; Vighetto A; Pugeat M; Borson-Chazot F
    Clin Endocrinol (Oxf); 2009 Apr; 70(4):588-92. PubMed ID: 18673461
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Successful treatment of a large macroprolactinoma with cabergoline during pregnancy.
    Liu C; Tyrrell JB
    Pituitary; 2001 Aug; 4(3):179-85. PubMed ID: 12138991
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Perifusion studies of bromocriptine-treated and untreated macroprolactinomas: effects of dopamine, bromocriptine and TRH.
    Bevan JS; Burke CW
    Clin Endocrinol (Oxf); 1989 Jun; 30(6):667-80. PubMed ID: 2512041
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A giant prolactinoma presenting with unilateral exophthalmos: effect of cabergoline and review of the literature.
    Berwaerts J; Verhelst J; Abs R; Appel B; Mahler C
    J Endocrinol Invest; 2000 Jun; 23(6):393-8. PubMed ID: 10908167
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
    Colao A; Di Sarno A; Landi ML; Cirillo S; Sarnacchiaro F; Facciolli G; Pivonello R; Cataldi M; Merola B; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3574-9. PubMed ID: 9360509
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Large macroprolactinoma treated with bromocriptine alone.
    Loh KC; Shlossberg AH
    Ann Acad Med Singap; 1996 Nov; 25(6):886-9. PubMed ID: 9055023
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Optimal testosterone level to improve symptoms of hypogonadism without causing dopa-testotoxicosis in male macroprolactinoma.
    Telci Caklili O; Ok AM; Istemihan Z; Selcukbiricik O; Yarman S
    Ann Endocrinol (Paris); 2022 Feb; 83(1):9-15. PubMed ID: 34871603
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Giant prolactinomas in men: efficacy of cabergoline treatment.
    Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
    Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pergolide as primary therapy for macroprolactinomas.
    Orrego JJ; Chandler WF; Barkan AL
    Pituitary; 2000 Dec; 3(4):251-6. PubMed ID: 11788013
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pasireotide: A potential therapeutic alternative for resistant prolactinoma.
    Lasolle H; Vasiljevic A; Borson-Chazot F; Raverot G
    Ann Endocrinol (Paris); 2019 Apr; 80(2):84-88. PubMed ID: 30318256
    [TBL] [Abstract][Full Text] [Related]  

  • 55. T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists.
    Burlacu MC; Maiter D; Duprez T; Delgrange E
    Endocrine; 2019 Feb; 63(2):323-331. PubMed ID: 30267354
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treating prolactinoma and psychosis: medication and cognitive behavioural therapy.
    Nieman DH; Sutterland AL; Otten J; Becker HE; Drent ML; van der Gaag M; Birchwood M; de Haan L
    BMJ Case Rep; 2011 Feb; 2011():. PubMed ID: 22715200
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of the Leksell gamma knife in the treatment of prolactinoma patients.
    Jezková J; Hána V; Krsek M; Weiss V; Vladyka V; Liscák R; Vymazal J; Pecen L; Marek J
    Clin Endocrinol (Oxf); 2009 May; 70(5):732-41. PubMed ID: 18710463
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure.
    Akinduro OO; Lu VM; Izzo A; De Biase G; Vilanilam G; Van Gompel JJ; Bernet V; Donaldson A; Olomu O; Meyer FB; Quinones-Hinojosa A; Chaichana KL
    World Neurosurg; 2019 Sep; 129():e686-e694. PubMed ID: 31181361
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Extensive experience in the management of macroprolactinomas.
    Green AI; Sherlock M; Stewart PM; Gittoes NJ; Toogood AA
    Clin Endocrinol (Oxf); 2014 Jul; 81(1):85-92. PubMed ID: 24483350
    [TBL] [Abstract][Full Text] [Related]  

  • 60. THE EFFECT OF RALOXIFENE ON SERUM PROLACTIN LEVEL IN PATIENTS WITH PROLACTINOMA.
    Choudhary C; Hamrahian AH; Bena JF; Recinos P; Kennedy L; Dobri G
    Endocr Pract; 2019 Jul; 25(7):684-688. PubMed ID: 30865525
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.